A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.
• Participants diagnosed (clinically) with type 2 diabetes mellitus (T2D) for at least 1 year prior to screening.
• Have been treated with basal-bolus multiple daily injection (MDI) therapy for at least 90 days prior to screening including:
‣ Basal insulin glargine U-100, in combination with bolus insulin analog (insulin lispro, insulin aspart, or insulin glulisine) with meals.
⁃ Participant must have been treated with the same type of allowed bolus insulin analog for at least 30 days prior to screening.
• Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) for T2D in accordance with local regulations:
∙ Metformin
‣ Dipeptidyl peptidase-4 (DPP-4) inhibitor
‣ sodium glucose cotransporter 2 (SGLT2) inhibitor
‣ oral glucagon-like peptide 1 (GLP-1) agonist
• Doses of OAMs are required to have been stable for at least 90 days prior to screening.
• Participants may be treated with injectable GLP-1 receptor agonist for T2D in accordance with local regulations. The GLP-1 receptor agonist dose is required to have been stable for at least 90 days prior to screening.
• Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.